# Freenome, Inc. (PCSC) — merger/spac_merger [completed]
Source: SEC API (secapi.ai) · situation sit_73078235b9fdf9677542 · retrieved 2026-08-11T16:15:06.614Z

## Overview
Freenome is a medical laboratory services company developing cancer detection tests using cell-free DNA analysis and machine learning.

On July 20, 2026, Perceptive Capital Solutions Corp (PCSC), a Cayman Islands exempted company, consummated a business combination with Freenome Holdings, Inc. pursuant to a business combination agreement dated December 5, 2025 and amended on July 20, 2026. The transaction involved PCSC's domestication as a Delaware corporation, followed by a two-step merger in which Merger Sub I merged with and into Freenome (with Freenome surviving), and then Freenome merged with and into Merger Sub II (with Merger Sub II surviving). Upon consummation, PCSC changed its corporate name to Freenome, Inc. New Freenome received gross proceeds of approximately $310.3 million in connection with the Business Combination, which included $70.3 million from PCSC's trust account and $240.0 million from a concurrent PIPE Investment. Freenome shareholders received shares of New Freenome Common Stock at an exchange ratio of approximately 0.282895.

## Terms
- Counterparty: Freenome Holdings, Inc. · Deal value: $310.3M · Consideration: mixed

## Key dates
- Announced 2026-03-02 · Expected close 2026-06-30 · Completed 2026-07-20

## Timeline
- 2026-03-02 · 425 (0001140361-26-007379): 425 - Perceptive Capital Solutions Corp — *Freenome Holdings, Inc. develops blood-based cancer detection tests, including colorectal cancer (CRC) and personalized, risk-based multi-cancer detection (P-MCD) tests; its CRC v1 test is in FDA review with anticipated mid-year approval in partnership with Exact Sciences/Abbott.* Freenome Holdings, Inc., a clinical-stage diagnostics company, is pursuing a proposed business combination with Perceptive Capital Solutions Corp (PCSC), a special-purpose acquisition company. The transaction is expected to close in the first half of 2026, subject to SEC review. Freenome is raising a $240 million PIPE (private investment in public equity) to fund the combined company. The company is on track for multiple 2026 milestones including FDA approval of its CRC v1 test (mid-year), CRC v2 final readout, sPMA submission, and commercial launches of multiple tests.
  https://www.sec.gov/Archives/edgar/data/2017526/0001140361-26-007379.txt
- 2026-07-20 · 25-NSE (0001354457-26-000709): 25-NSE
  https://www.sec.gov/Archives/edgar/data/2017526/000135445726000709/xslF25X02/primary_doc.xml
- 2026-07-24 · 8-K (0001140361-26-029471): 8-K - Freenome, Inc. — *Freenome is a medical laboratory services company developing cancer detection tests using cell-free DNA analysis and machine learning.* On July 20, 2026, Perceptive Capital Solutions Corp (PCSC), a Cayman Islands exempted company, consummated a business combination with Freenome Holdings, Inc. pursuant to a business combination agreement dated December 5, 2025 and amended on July 20, 2026. The transaction involved PCSC's domestication as a Delaware corporation, followed by a two-step merger in which Merger Sub I merged with and into Freenome (with Freenome surviving), and then Freenome merged with and into Merger Sub II (with Merger Sub II surviving). Upon consummation, PCSC changed its corporate name to Freenome, Inc. New Freenome received gross proceeds of approximately $310.3 million in connection with the Business Combination, which included $70.3 million from PCSC's trust account and $240.0 million from a concurrent PIPE Investment. Freenome shareholders received shares of New Freenome Common Stock at an exchange ratio of approximately 0.282895.
  https://www.sec.gov/Archives/edgar/data/2017526/0001140361-26-029471.txt

## Citations
- 0001140361-26-007379 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126007379
- 0001354457-26-000709 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000135445726000709
- 0001140361-26-029471 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029471